Why is Island Pharmaceuticals stock rallying today?
- Investing.com
Metrics to compare | ILA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipILAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.0x | −6.0x | −0.2x | |
PEG Ratio | 0.15 | −0.08 | 0.00 | |
Price/Book | 6.6x | 1.9x | 2.6x | |
Price / LTM Sales | 314.3x | 4.4x | 2.7x | |
Upside (Analyst Target) | - | 446.7% | 69.6% | |
Fair Value Upside | Unlock | 19.5% | 11.7% | Unlock |
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for infectious diseases in Australia and the United States. The company’s lead product candidate is ISLA-101, a drug which is in second clinical-stage for the prevention and treatment of dengue fever and other mosquito vector borne diseases; and Galidesivir, a spectrum antiviral candidate with the potential to address multiple high-priority RNA virus threats. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia.